RxDoctor Payments Data

Magdalene Kelly, PA

Physician Assistant · Wilmington, NCNPI 1942800370

Payments from drug & device makers

$3,145in general payments, 2019–2025

Across 168 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$309
  • Takeda Pharmaceuticals U.S.A., Inc.$224
  • Bristol Myers Squibb$155
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$153
  • Janssen Scientific Affairs, LLC$118
  • plus $699 from 15 others

What the payments were for

  • Food & beverage$3,131100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,145 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$32,828
Medicare patients
295
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab23$645,195
LinzessLinaclotide21$25,117
Lubiprostone25$3,757
Colestipol Hcl39$3,262
Omeprazole196$2,500
Famotidine134$1,951
Esomeprazole Magnesium36$1,870
Pantoprazole Sodium83$1,690
Sucralfate15$1,523
Dicyclomine Hcl21$403
LoperamideLoperamide Hcl15$393
Amitriptyline Hcl14$172
Furosemide12$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$309$645,19523 claims
AbbVieLinzess$1,488$25,11721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →